Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
Crossref DOI link: https://doi.org/10.1007/s41669-017-0031-6
Published Online: 2017-06-01
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sabale, Ugne
Ekman, Mattias
Thunström, Daniel
Telford, Claire
Livings, Christopher
Funding for this research was provided by:
AstraZeneca Nordic-Baltic
License valid from 2017-06-01